GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...

Responding to growing pressure, ViiV Healthcare announced steps to widen access to its HIV prevention medicine in low- and ...

Faced with a moribund share sale outlook and emboldened by their growing recognition on the global stage, some Chinese ...

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...